Biocon Biologics launches ustekinumab biosimilar in US
Yesintek is claimed to be one of the first Stelara (ustekinumab) biosimilar market entrants in the US. The therapy gained approval for treating various conditions which includes Crohn’s
The US Food and Drug Administration (FDA) has granted fast track designation for Avobis Bio’s lead therapeutic candidate, AVB-114, for treating Crohn's perianal fistulas.
Investors for the funding round include Johnson & Johnson Innovation, Deerfield Management, Catalio Capital Management, Braidwell, the Retinal Degeneration Fund, and GV. The company is dedicated to advancing
As part of this collaboration, Boehringer will utilise ExpressionEdits’ AI-powered platform, Genetic Syntax Engine, designed to boost gene expression without altering the genetic sequence, for the development of